Subscribe
Share
Share
Embed
In this episode, we’re joined by Dr. Nicolas Garnier (French pronunciation: [ni.ko.la]) who’ll tell us a bit about himself and his work as consortium lead with Screen4Care.
Welcome to this episode of Signalise: a Dazzle4Rare podcast. In this episode, we’re joined by Dr. Nicolas Garnier (French pronunciation: [ni.ko.la]) who’ll tell us a bit about himself and his work.
We’d planned to discuss Dr. Garnier’s work in new-born screening and the topic broadly but I couldn’t help myself; I wanted to get a more full understanding on his current project, Screen4Care where he is the consortium lead.
I think of Dazzle4Rare as a community service to our rare and associated communities so I’m glad that I dug in a little bit deeper during this chat and I hope you’ll enjoy our conversation. In fact, I’d like to have him back for a future follow-up episode so if you have questions you’d like Dr. Garnier to answer, email them over!
For those hoping to hear our TL;DR segment, Rare and Relevant, there will be a bonus episode today covering those news items. I hope you’ll listen to both but if you’re looking for some R and R, head over to that episode for what’s happening in our global community.
Links from Dr. Garnier
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893317/
A few additional good resources:
https://www.eurordis.org/our-priorities/diagnosis/newborn-screening/ https://download2.eurordis.org/documents/pdf/eurordis_nbs_position_paper.pdf
---
Don't miss an episode of Signalise! Be sure to ✔️FOLLOW or ✔️SUBSCRIBE via your podcast app of choice. You can also follow #Signalise news on @Dazzle4Rare on Facebook , Instagram , and Twitter. You can find host Kimberly on LinkedIn at @kattague.
The Dazzle4Rare event and Signalise podcast amplify the voices of rare disease and associated communities by sharing their stories, new, events, and more. Working together, we have strength in numbers, amplifying our critical messages.
We feature guests and discuss relevant topics for rare disease patients, caregivers, and those in the URCIID community.